Cargando…

COVID-19 Vasculopathy and Post–COVID-19 Phenomenon: Reply

Detalles Bibliográficos
Autor principal:	Akgul, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by The Society of Thoracic Surgeons Published by Elsevier 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546689/ https://www.ncbi.nlm.nih.gov/pubmed/33875138 http://dx.doi.org/10.1016/j.athoracsur.2020.09.008

Ejemplares similares

Reply to: COVID-19 and Coagulopathy
por: Rodríguez, Cristina, et al.
Publicado: (2021)

Rumpel-Leede Phenomenon in a COVID-19 Patient
por: Chaitanya, Pratapaneni VK, et al.
Publicado: (2022)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

On Ventricular Aneurysms, Thrombi, and COVID-19: Reply
por: Hui, Dawn S., et al.
Publicado: (2021)

Surgical Training in the Era of COVID-19: Reply
por: Fuller, Stephanie
Publicado: (2021)

COVID-19 and preterm birth – Authors' reply
por: Choudhary, Rahul, et al.
Publicado: (2021)

Neuropsychiatric disorders and COVID-19 – Authors' reply
por: Taquet, Maxime, et al.
Publicado: (2021)

COVID-19 and myocardial infarction – Authors' reply
por: Katsoularis, Ioannis, et al.
Publicado: (2021)

COVID-19 research in LMICs – Authors' reply
por: Torres, Irene, et al.
Publicado: (2021)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Reply: COVID-19, A and Hypersensitivity Pneumonitis
por: Shin, Hyoung-Shik
Publicado: (2020)

Reply to Epelbaum: Standards and Stereotypes in COVID-19
por: Ziehr, David R., et al.
Publicado: (2020)

In Reply to ‘COVID-19–Associated Kidney Injury’
por: Patel, Niralee, et al.
Publicado: (2020)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Prone Positioning in COVID-19 ARDS: Reply
por: Zarantonello, Francesco, et al.
Publicado: (2023)

Reply to: “Liver fibrosis and adverse outcomes in COVID-19”
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021)

COVID-19: from hospitals to courts – Author's reply
por: Usuelli, Michele
Publicado: (2021)

Azithromycin for mild-to-moderate COVID-19 – Authors' reply
por: Hinks, Timothy S C
Publicado: (2021)

Antipsychotics and COVID-19: the debate goes on – Authors' reply
por: De Picker, Livia, et al.
Publicado: (2021)

WHO COVID-19 therapeutic guidelines – Authors' reply
por: White, Nicholas J, et al.
Publicado: (2021)

COVID-19 and global mental health – Authors' reply
por: Kola, Lola, et al.
Publicado: (2021)

COVID-19 and maternal and perinatal outcomes – Authors' reply
por: Chmielewska, Barbara, et al.
Publicado: (2021)

Combining immunomodulators and antivirals for COVID-19 – Authors' reply
por: Almansa, Raquel, et al.
Publicado: (2021)

Frailty and mortality in patients with COVID-19 – Authors' reply
por: McCarthy, Kathryn, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Reply to: Ivermectin in COVID-19. Argumentum ad ignorantiam?()
por: López Reboiro, M.L., et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Psychiatric and neuropsychiatric syndromes and COVID-19 – Authors' reply
por: Rogers, Jonathan P, et al.
Publicado: (2020)

Management of diabetes in patients with COVID-19 – Authors' reply
por: Bornstein, Stefan R, et al.
Publicado: (2020)

Surgery during the COVID-19 pandemic – Authors' reply
por: COVIDSurg Collaborative
Publicado: (2020)

Depression and anxiety during COVID-19 – Authors' reply
por: Santomauro, Damian F, et al.
Publicado: (2022)

Reply to ‘Use of convalescent plasma in the treatment of COVID-19’
por: Murakami, Naoka, et al.
Publicado: (2023)

Vasculopathy in COVID-19
por: Flaumenhaft, Robert, et al.
Publicado: (2022)

Reply to "Does MAFLD really increase the severity of COVID-19?"
por: Pan, Lu, et al.
Publicado: (2021)

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply
por: Leisman, Daniel E, et al.
Publicado: (2021)

Reply to: Neuroimmune interactions and COVID-19 in lung transplant recipients
por: De Virgiliis, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jgeg832k8pd6p0mj202e90nc2c